How is infantile hemangioma treated?

Hemangiomas are health conditions arising from multiple underlying factors, and in most cases, they manifest with noticeable symptoms on the skin. Once a hemangioma develops, prompt treatment is essential—delayed intervention may lead to significant complications for the patient. Below, we detail three commonly used treatment approaches for pediatric hemangiomas!

How Are Hemangiomas Treated in Children?

1. Surgical Treatment

Surgical excision is the primary surgical approach. First, after lesion removal, skin grafting is often required—typically using full-thickness or split-thickness skin grafts, which yield favorable outcomes. However, the inner aspect of the upper arm is the preferred donor site for graft harvesting. Second, for larger lesions, direct wound closure following excision of port-wine stains is usually not feasible; instead, adjacent tissue flaps may be used for reconstruction, or tissue expansion therapy may be employed. In the latter case, a tissue expander is implanted around the lesion and gradually inflated over 2–3 months until sufficient local skin expansion is achieved, enabling subsequent reconstruction.

2. Laser Therapy

Q-switched pulsed dye lasers operating at a wavelength of 585 nm—with optimal pulse duration and variable spot sizes—are particularly effective for treating various dermatologic conditions. The 585-nm laser light corresponds to the peak absorption wavelength of hemoglobin, allowing penetration through the epidermis into the dermis. Its ultrashort pulse duration selectively destroys capillaries while minimizing thermal injury to surrounding tissues, thereby reducing the risk of scarring.

3. Photodynamic Therapy (PDT) with Fumaderm® (Hemoporfin)

This modality involves intravenous administration of Hemoporfin—the second-generation photosensitizer. Following injection, Hemoporfin rapidly reaches peak plasma concentration and is preferentially taken up by vascular endothelial cells, whereas epidermal keratinocytes absorb relatively little. This results in a marked concentration gradient between vascular endothelium and epidermis. Subsequent irradiation with a specific wavelength of light—shallow-penetrating and selectively absorbed by endothelial cells—activates Hemoporfin to generate cytotoxic singlet oxygen and other reactive oxygen species. Consequently, the dilated, malformed capillary networks characteristic of hemangiomas are selectively destroyed, while the overlying normal epidermis remains unharmed (due to its low Hemoporfin content). Moreover, deeper dermal structures beneath the abnormal vasculature are spared, as the activating light penetrates only superficially and fails to deliver an effective dose at those depths.

It bears emphasis that early intervention for hemangiomas is critical: the earlier treatment begins, the better the therapeutic outcome and the faster the recovery. Early treatment also minimizes adverse effects on the child’s development. Conversely, delayed management risks disease progression and worsening clinical outcomes!